NCT05338970: An ongoing trial by Daiichi Sankyo
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05338970 |
|---|---|
| Title | A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 8, 2022 |
| Completion date | May 31, 2024 |
| Required reporting date | May 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |